Our Pricing

Mounjaro vs Ozempic: Which Has Safer Side Effects?

When comparing mounjaro vs ozempic side effects UK, both medications share similar gastrointestinal side effects, but their safety profiles differ in frequency and severity. At Cured Pharmacy, our UK-registered clinical team helps patients understand these differences through free online consultations, ensuring you choose the treatment that aligns with your medical history and tolerance.

Understanding How Mounjaro and Ozempic Work Differently

Mounjaro (tirzepatide) is the UK's first dual GIP/GLP-1 receptor agonist, whilst Ozempic (semaglutide) activates only the GLP-1 pathway [1]. This fundamental difference influences not just efficacy but also the side effect profile patients experience during treatment.

Both medications slow gastric emptying and reduce appetite through similar mechanisms, which explains why they share common gastrointestinal side effects [1]. However, tirzepatide's dual-receptor action produces different hormonal responses that may affect how your body tolerates the medication over time.

In the SURPASS-2 head-to-head trial comparing tirzepatide directly against semaglutide, researchers documented side effect frequencies at equivalent doses, providing the most reliable safety comparison available [2]. Understanding these trial results helps UK patients and prescribers make evidence-based treatment decisions.

Common Side Effects: Mounjaro vs Ozempic Comparison

The most frequently reported side effects for both medications are gastrointestinal: nausea, vomiting, diarrhoea, and constipation [1][2]. In clinical trials, nausea occurred in approximately 18-29% of Mounjaro patients compared to 15-20% of Ozempic patients, depending on the dose prescribed.

Diarrhoea was reported by 13-23% of tirzepatide users versus 9-12% of semaglutide users in comparative studies [2]. Whilst these percentages appear higher for Mounjaro, most gastrointestinal side effects were mild to moderate and decreased significantly after the first 4-8 weeks of treatment.

Vomiting rates showed similar patterns, with 6-10% of Mounjaro patients experiencing this side effect compared to 5-9% on Ozempic [2]. UK prescribers typically start both medications at lower doses and increase gradually to minimise these effects, a strategy that has proven effective in reducing discontinuation rates.

Managing Gastrointestinal Side Effects

Most patients find gastrointestinal symptoms improve substantially within the first month as their body adjusts to treatment. Eating smaller, more frequent meals and avoiding high-fat foods can help reduce nausea and stomach discomfort during the initial titration period.

Your UK prescriber may recommend staying at a lower dose for an additional week or two if side effects feel overwhelming. This personalised dose escalation approach, supported by clinical evidence, helps maximise treatment adherence whilst minimising discomfort [3].

Serious Side Effects and Safety Considerations

Both Mounjaro and Ozempic carry warnings for rare but serious side effects including pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in animal studies but not confirmed in humans) [1][4]. The MHRA requires these warnings on all GLP-1 and dual-agonist medications licensed in the UK.

Acute pancreatitis occurred in less than 0.2% of patients in clinical trials for both medications, with no significant difference between tirzepatide and semaglutide [2]. Patients should seek immediate medical attention if they experience severe abdominal pain that doesn't resolve, as this may indicate pancreatitis.

Hypoglycaemia (low blood sugar) risk remains low with both medications when used alone for weight management, but increases if combined with insulin or sulphonylureas [1]. UK prescribers carefully review your complete medication list during consultation to identify and manage potential drug interactions.

Which Medication Has Better Tolerability?

In the SURPASS-2 trial, discontinuation rates due to adverse events were 6.2% for tirzepatide 10mg, 7.1% for tirzepatide 15mg, and 3.7% for semaglutide 1mg [2]. Whilst these figures suggest slightly higher discontinuation with Mounjaro at maximum doses, the difference wasn't statistically significant when accounting for the greater weight loss achieved.

When evaluating tolerability, UK clinicians consider not just side effect frequency but also treatment satisfaction and quality of life improvements. Patients achieving greater weight loss often report higher overall satisfaction despite experiencing similar or slightly more frequent gastrointestinal symptoms [2].

Individual response varies considerably, and some patients tolerate one medication better than the other regardless of clinical trial averages. Your medical history, current medications, and personal preferences all influence which treatment your UK prescriber recommends during your consultation.

Factors Affecting Your Personal Tolerance

Pre-existing gastrointestinal conditions, previous experience with similar medications, and your baseline eating patterns all influence how you'll respond to treatment. Patients with a history of gastroparesis or severe reflux may require additional monitoring or alternative treatments.

Age, kidney function, and body weight also affect medication tolerance and dosing requirements. UK prescribers assess these factors during your online consultation to determine the safest starting dose and escalation schedule for your individual circumstances.

Clinical Trial Safety Data: What the Evidence Shows

The SURPASS clinical trial programme enrolled over 10,000 participants across multiple studies, providing extensive safety data for tirzepatide [2]. The STEP trials for semaglutide included approximately 4,500 participants, also demonstrating robust safety monitoring [5].

Both trial programmes followed participants for 40-72 weeks, documenting side effects throughout the treatment period [2][5]. This extended follow-up revealed that most adverse events occurred during dose escalation, with significantly fewer new side effects emerging after patients reached their maintenance dose.

Cardiovascular safety assessments showed no increased risk of major adverse cardiovascular events (MACE) for either medication, and some trials suggested potential cardiovascular benefits [4]. The MHRA continues to monitor post-marketing safety data as these medications are prescribed more widely across the UK.

Making Your Decision: Mounjaro vs Ozempic at Cured Pharmacy

At Cured Pharmacy, we offer Mounjaro from £135.00 following a free online consultation with our UK-registered prescribers. Our clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews your complete medical history to determine which treatment offers the best balance of efficacy and tolerability for your circumstances.

The consultation process takes under three minutes and includes detailed questions about your weight loss goals, previous medication experiences, and any gastrointestinal or other health conditions that might influence treatment selection. This thorough assessment ensures you receive a prescription that's both safe and appropriate.

We also offer alternative weight loss treatments including Wegovy (semaglutide) and Saxenda (liraglutide), allowing your prescriber to recommend the most suitable option based on your individual profile. All medications dispensed are UK-licensed, and we guarantee 100% discreet packaging with competitive pricing across our entire weight loss range.

Starting Your Treatment Safely

Your UK prescriber will determine your starting dose based on clinical guidelines and your personal medical history. Most patients begin with the lowest available dose to minimise side effects, gradually increasing every four weeks as tolerated until reaching the optimal therapeutic dose.

Our pharmacy team provides detailed injection technique guidance and side effect management advice with every prescription. You'll have access to ongoing support throughout your treatment journey, ensuring any concerns are addressed promptly by qualified healthcare professionals.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK.
2. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398(10295), 64–77. https://doi.org/10.1016/S0140-6736(21)01324-6
3. Aroda, V. R., et al. (2023). Efficacy and Safety of Once-Weekly Tirzepatide in People with Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes, Obesity and Metabolism, 25(3), 641–651. https://doi.org/10.1111/dom.14920
4. National Institute for Health and Care Excellence. (2023). Tirzepatide for Treating Type 2 Diabetes: Technology Appraisal Guidance [TA924]. NICE.
5. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.